FDA Grants Bright Path AMT Designation as It Moves to Reshore America’s Medicines and Reduce Reliance on China

The designation covers Bright Path’s end-to-end U.S. production of two hospital medicines in chronic shortage, the first proof that essential medicines can be made in America, in most cases at prices that beat China and Indi